SWOG Cancer Research Network
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, SWOG Cancer Research Network sits in the top decile of US sponsors by registered trial count (#125 of 15,742 sponsors by registered trial count).
SWOG Cancer Research Network: 270 sponsored US clinical trials, 28 recruiting.
SWOG Cancer Research Network sponsors 270 registered US clinical trials on ClinicalTrials.gov, 28 of them currently recruiting, and 181 completed. 68 of these trials are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 10 trials.
Top-decile sponsor footprint
SWOG Cancer Research Network ranks in the top decile of sponsors by registered trial count (#125 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
181 of 221 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
270 total, page 4 of 6
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
NCT00086996
S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer
NCT00090961
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00066794
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00085501
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
NCT00085709
S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000
NCT00784225
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
NCT00075764
FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
NCT00077337
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
NCT00070018
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
NCT00075686
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
NCT00064337
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
NCT00068367
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
NCT00919139
S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
NCT00049400
Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
NCT00068289
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
NCT00033540
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
NCT00062439
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00054054
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00049179
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00053833
S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia
NCT00053014
S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed
NCT00049335
S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat
NCT00017173
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
NCT00045630
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
NCT00045617
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
NCT00045162
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
NCT00055835
Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00042783
S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
NCT00041067
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
NCT00043082
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
NCT00032123
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00040937
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
NCT00900263
Arsenic Trioxide in Treating Men With Germ Cell Cancer
NCT00036842
S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00030433
S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
NCT00032084
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00028769
S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00026156
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
NCT00026520
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
NCT00006994
S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
NCT00017147
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome
NCT00016419
S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
NCT00023777
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
NCT00016965
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
NCT00006392
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
NCT00022633
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00016393
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
NCT00023634
S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
NCT00015938
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00016939
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 155 |
| Phase 3 | 68 |
Therapeutic Areas
What is open in the SWOG Cancer Research Network pipeline
28 recruiting of 270 indexed (10% open); 181 completed (67%).
Phase mix: 68 late (III/IV) vs 164 early (I/II) (early-phase heavy).
Top condition: Lung Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
SWOG Cancer Research Network: open-pipeline peers nationwide
Peers matched on 270 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
SWOG Cancer Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 270 trials (± recruiting share)
- Alcon Research · 275 trials · 2% recruiting
- Novartis · 265 trials · 0% recruiting
- Abbott Medical Devices · 261 trials · 9% recruiting
- Boston Scientific Corporation · 280 trials · 8% recruiting
Sponsors near 10% open enrollment (± trial volume)
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
- University of Rhode Island · 10% recruiting · 29 trials
- University of Mississippi Medical Center · 10% recruiting · 96 trials
Related
What to do with this SWOG Cancer Research Network page
270 registered trials is a research-attention snapshot, not an endorsement of SWOG Cancer Research Network or any single study.
- 28 of SWOG Cancer Research Network's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer is the condition SWOG Cancer Research Network studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. SWOG Cancer Research Network pipeline card: 270 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.